Relative importance of PSA in prostate cancer treatment.

[1]  J. Morote,et al.  Nadir prostate‐specific antigen best predicts the progression to androgen‐independent prostate cancer , 2004, International journal of cancer.

[2]  S. Balk,et al.  Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.

[3]  A. D'Amico,et al.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Loening,et al.  CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer , 2004, The Prostate.

[5]  C. Parker.  Active surveillance: towards a new paradigm in the management of early prostate cancer. , 2004, The Lancet. Oncology.

[6]  K. Pienta,et al.  Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. , 2003, Urology.

[7]  J. Walczak,et al.  Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Grou , 2003, Urology.

[8]  D. Lubeck,et al.  Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. , 2003, The Journal of urology.

[9]  H Augustin,et al.  Disease recurrence after radical prostatectomy. Contemporary diagnostic and therapeutical strategies. , 2003, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[10]  M. Wirth,et al.  Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. , 2003, European urology.

[11]  C. Catton,et al.  Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management. , 2003, The Urologic clinics of North America.

[12]  H. Sandler,et al.  What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? , 2003, Urology.

[13]  Pierre I Karakiewicz,et al.  International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Neil Fleshner,et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.

[15]  P. Schellhammer,et al.  Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. , 2001, The Journal of urology.

[16]  J. Blasko,et al.  Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.

[17]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[18]  M W Kattan,et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[20]  A. Hanlon,et al.  Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[21]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[22]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[23]  A. Renshaw,et al.  Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Cella,et al.  Eastern Cooperative Oncology Group (ECOG). , 1996, Journal of the National Cancer Institute. Monographs.